combined vaccines

Summary

Alias: combination vaccines
Summary: Two or more vaccines in a single dosage form.

Webpages

  1. vaccines. table of contents
    healthlinks.washington.edu/index.jsp?id=A2E7B499-C6FB-4FA3-B ...
  2. department of pediatrics :: duke faculty
    pediatrics.duke.edu/modules/dukefaculty/viewDetails.php?u=01 ...
  3. prévenir les maladies infectieuses
    www.santepub-mtl.qc.ca/Mi/public/coqueluche/indexang.html
  4. fda approval of use of a new haemophilus b conjugate vaccine and a combined diphtheria-tetanus-pertussis and haemophilus b conjugate vaccine for infants and children
    www.cdc.gov/MMWR/preview/mmwrhtml/00020301.htm
  5. vaccines: pubs/acip recommendations
    www.cdc.gov/vaccines/pubs/acip-list.htm
  6. acip: use of haemophilus b conjugate vaccines
    aepo-xdv-www.epo.cdc.gov/wonder/prevguid/p0000326/p0000326.a ...
  7. centro de ingeniería genética y biotecnológica - laboratory of biological assays i
    www.cigb.edu.cu/index.php?option=com_content&task=view&id=74 ...
  8. sheep 201: flock vaccinations
    www.sheep101.info/201/vaccinations.html
  9. utm's m.biotech class of 2006 presents: "biotechnology in developing countries
    www.utm.utoronto.ca/mbiotech/Symposium2004/speakers.html
  10. institute for vaccine safety - 2008 immunization schedule
    www.vaccinesafety.edu/2008-schedule-0-6.htm

Research Grants

  1. Transmissible Spongiform Encephalopathies: Product Safet
    David M Asher; Fiscal Year: 2003
  2. Evaluation of safety and consistentency of biological pr
    Konstantin M Chumakov; Fiscal Year: 2003
  3. Regulation of the Immune Response to Polysaccharides and
    K E Stein; Fiscal Year: 2002
  4. Development of innovative statistical approaches to biol
    Rolf E Taffs; Fiscal Year: 2002
  5. Conjugation Chemistries for Attachment of Polysaccharide
    Robert C Lee; Fiscal Year: 2002
  6. Methods for evaluation of immunogencity and efficacy of
    Konstantin M Chumakov; Fiscal Year: 2002
  7. Combinatorial vaccines against anthrax and plague
    John D Clements; Fiscal Year: 2006
  8. Serologic studies of host response to pertussis vaccines
    Bruce D Meade; Fiscal Year: 2002
  9. AAV-Based Plasmacytoid Dendritic Cell Cancer Vaccine
    Pierre L Triozzi; Fiscal Year: 2008
  10. AAV-Based Plasmacytoid Dendritic Cell Cancer Vaccine
    Pierre L Triozzi; Fiscal Year: 2007

Publications

  1. Antibody persistence in five-year-old children who received a pentavalent combination vaccine in infancy
    Rose Marie Carlsson
    Department of Infectious Diseases, Sahlgrenska University Hospital Ostra, Göteborg, Sweden
    Pediatr Infect Dis J 21:535-41
  2. A new DTPw-HB/Hib combination vaccine for primary and booster vaccination of infants in Latin America
    Miguel Tregnaghi
    Centro de Desarrollo de Proyectos Avanzados, Córdoba, Argentina
    Rev Panam Salud Publica 19:179-88
  3. Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa-HBV-IPV/Hib vaccine
    T Nolan
    Murdoch Children s Research Institute, The University of Melbourne, VIC 3010, Australia
    Vaccine 23:14-20
  4. A new DTPw-HBV/Hib vaccine: immune memory after primary vaccination and booster dosing in the second year of life
    Salvacion Gatchalian
    Research Institute for Tropical Medicine, Filinvest Corporate Centre, Alabang, Muntinlupa City, Manila, Philippines
    Hum Vaccin 4:60-6
  5. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine
    Heng Kock Cheng
    KK Women's and Children Hospital, Singapore
    Southeast Asian J Trop Med Public Health 35:685-92
  6. Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine
    Michael E Pichichero
    University of Rochester Medical Center, Rochester, New York 14642, USA
    J Pediatr 151:43-9, 49.e1-2
  7. Immunogenicity of a combined DTPa-HB vaccine co-administered with Haemophilus influenzae type B conjugate vaccine (PRP-T) for primary and booster vaccinations
    Humberto Bracco Neto
    Department of Pediatrics, Federal University of São Paulo, Rua Correa de Lemos 780, São Paulo, SP, Brazil
    Braz J Infect Dis 9:363-73
  8. Assessment of the compatibility of co-administered 7-valent pneumococcal conjugate, DTaP.IPV/PRP-T Hib and hepatitis B vaccines in infants 2-7 months of age
    David W Scheifele
    Vaccine Evaluation Center, BC Children s Hospital, 4500 Oak Street, Vancouver, BC, Canada V6H 3N1
    Vaccine 24:2057-64
  9. Safety and immunogenicity of a primary course and booster dose of a combined diphtheria, tetanus, acellular pertussis, hepatitis B and inactivated poliovirus vaccine
    Sirli Meriste
    Department of Infectious Diseases, Children s Clinic of Tartu University Hospital, Tartu, Estonia
    Scand J Infect Dis 38:350-6
  10. Clinical experience with DTPw-HBV and DTPw-HBV/Hib combination vaccines
    Roman Prymula
    University of Defense, Department of Epidemiology, Faculty of Military Health Science, Hradec Kralove, Czech Republic
    Expert Opin Biol Ther 8:503-13

Scientific Experts

Detail Information

Webpages22

  1. vaccines. table of contents
    healthlinks.washington.edu/index.jsp?id=A2E7B499-C6FB-4FA3-B ...
  2. department of pediatrics :: duke faculty
    pediatrics.duke.edu/modules/dukefaculty/viewDetails.php?u=01 ...
  3. prévenir les maladies infectieuses
    www.santepub-mtl.qc.ca/Mi/public/coqueluche/indexang.html
  4. fda approval of use of a new haemophilus b conjugate vaccine and a combined diphtheria-tetanus-pertussis and haemophilus b conjugate vaccine for infants and children
    www.cdc.gov/MMWR/preview/mmwrhtml/00020301.htm
  5. vaccines: pubs/acip recommendations
    www.cdc.gov/vaccines/pubs/acip-list.htm
  6. acip: use of haemophilus b conjugate vaccines
    aepo-xdv-www.epo.cdc.gov/wonder/prevguid/p0000326/p0000326.a ...
  7. centro de ingeniería genética y biotecnológica - laboratory of biological assays i
    www.cigb.edu.cu/index.php?option=com_content&task=view&id=74 ...
  8. sheep 201: flock vaccinations
    www.sheep101.info/201/vaccinations.html
  9. utm's m.biotech class of 2006 presents: "biotechnology in developing countries
    www.utm.utoronto.ca/mbiotech/Symposium2004/speakers.html
  10. institute for vaccine safety - 2008 immunization schedule
    www.vaccinesafety.edu/2008-schedule-0-6.htm
  11. pentetic acid
    lib.bioinfo.pl/meid:77247
  12. centro de ingeniería genética y biotecnológica - formulation and package development department
    www.cigb.edu.cu/index.php?option=com_content&task=view&id=69 ...
  13. pentetic acid
    buchta.lib.bioinfo.pl/meid:77247
  14. centro de ingeniería genética y biotecnológica - formulation and package development department
    www.cigb.edu.cu/index.php?option=com_content&task=view&id=69 ...
  15. sanofi pasteur : about us - history & heritage
    www.sanofipasteur.com/sanofi-pasteur2/front/index.jsp?siteCo ...
  16. sanofi pasteur : about us - history & heritage
    www.sanofipasteur.com/sanofi-pasteur2/front/index.jsp?siteCo ...
  17. sanofi pasteur : about us - history & heritage
    www.sanofipasteur.com/sanofi-pasteur2/front/index.jsp?siteCo ...
  18. vaccine schedule : vaccine education center - children's hospital of philadelphia
    www.chop.edu/consumer/jsp/division/generic.jsp?id=75700
  19. dynavax technologies :: about us :: dynavax europe
    www.dvax.com/europe.html
  20. aap - national infant immunization week
    www.aap.org/family/immunwk.htm

Research Grants12

  1. Transmissible Spongiform Encephalopathies: Product Safet
    David M Asher; Fiscal Year: 2003
    ..an assessment of inhibition of immune response to inactivated polioviruses by other components of combined vaccines; 3...
  2. Evaluation of safety and consistentency of biological pr
    Konstantin M Chumakov; Fiscal Year: 2003
    ..Direct evaluation of efficacy of these new IPV as well as of combination vaccines containing IPV component is not possible, and therefore any regulatory actions should rely on surrogate ..
  3. Regulation of the Immune Response to Polysaccharides and
    K E Stein; Fiscal Year: 2002
    ..To meet this goal several combined vaccines have been tested for their safety and immunogenicity in infants...
  4. Development of innovative statistical approaches to biol
    Rolf E Taffs; Fiscal Year: 2002
    ..an assessment of inhibition of immune response to inactivated polioviruses by other components of combined vaccines; 3...
  5. Conjugation Chemistries for Attachment of Polysaccharide
    Robert C Lee; Fiscal Year: 2002
    ..may be useful for studying the effects of carrier suppression of conjugate vaccines, and interference in the combined vaccines. In other research, we have conjugated LPS from mutants of group B menigococci and B. pertussis to TT...
  6. Methods for evaluation of immunogencity and efficacy of
    Konstantin M Chumakov; Fiscal Year: 2002
    ..Direct evaluation of efficacy of these new IPV as well as of combination vaccines containing IPV component is not possible, and therefore any regulatory actions should rely on surrogate ..
  7. Combinatorial vaccines against anthrax and plague
    John D Clements; Fiscal Year: 2006
    ..number of immunizations and to increase vaccine coverage is not a new concept in vaccine development and combination vaccines such as DTP and MMR have been used for many years...
  8. Serologic studies of host response to pertussis vaccines
    Bruce D Meade; Fiscal Year: 2002
    ..Progress in the development and licensing of less reactogenic acellular pertussis vaccines, as well as combination vaccines containing an acellular pertussis component, was hindered by the lack of a laboratory correlate of clinical ..
  9. AAV-Based Plasmacytoid Dendritic Cell Cancer Vaccine
    Pierre L Triozzi; Fiscal Year: 2008
    ..determine the role of pDC activation in anti-tumor immunity elicited by effective rAAV-CEA and TLR agonist combination vaccines. The ability of this vaccine approach to elicit CEA-specific, antitumor, cellular immunity and the ..
  10. AAV-Based Plasmacytoid Dendritic Cell Cancer Vaccine
    Pierre L Triozzi; Fiscal Year: 2007
    ..determine the role of pDC activation in anti-tumor immunity elicited by effective rAAV-CEA and TLR agonist combination vaccines. The ability of this vaccine approach to elicit CEA-specific, antitumor, cellular immunity and the ..
  11. Phase 1b Active Immunotherapy with HER-2 Multi-epitope v
    PRAVIN TP KAUMAYA; Fiscal Year: 2003
    ..Aim 2:To determine whether both humoral and cellular immune responses are elicited in patients immunized with combination vaccines and nor-MDP as adjuvant and to study the underlying mechanisms of anti-tumor activity in vitro and in vivo.

Publications62

  1. Antibody persistence in five-year-old children who received a pentavalent combination vaccine in infancy
    Rose Marie Carlsson
    Department of Infectious Diseases, Sahlgrenska University Hospital Ostra, Göteborg, Sweden
    Pediatr Infect Dis J 21:535-41
    ..CONCLUSION: We found the persistence of antibodies satisfactory, with no clinically relevant differences in antibody concentrations demonstrated between children vaccinated according to a three dose or a four dose schedule in infancy...
  2. A new DTPw-HB/Hib combination vaccine for primary and booster vaccination of infants in Latin America
    Miguel Tregnaghi
    Centro de Desarrollo de Proyectos Avanzados, Córdoba, Argentina
    Rev Panam Salud Publica 19:179-88
    ..CONCLUSIONS: Our results indicate that the new DTPw-HB/Hib pentavalent combination vaccine provides an efficient and reliable way of implementing WHO recommendations for controlling hepatitis B and Hib infections on a worldwide basis...
  3. Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa-HBV-IPV/Hib vaccine
    T Nolan
    Murdoch Children s Research Institute, The University of Melbourne, VIC 3010, Australia
    Vaccine 23:14-20
    ..5% of booster recipients experienced >50-mm local swelling at the site of DTPa vaccination. We conclude that DTPa-HBV-IPV/Hib is safe and immunogenic for primary vaccination, and that Hib-specific memory is induced by primary vaccination...
  4. A new DTPw-HBV/Hib vaccine: immune memory after primary vaccination and booster dosing in the second year of life
    Salvacion Gatchalian
    Research Institute for Tropical Medicine, Filinvest Corporate Centre, Alabang, Muntinlupa City, Manila, Philippines
    Hum Vaccin 4:60-6
    ..Combined DTPw-HBV and DTPw-HBV/Hib vaccines using new vaccine antigen sources will promote continued supply of combined DTPw-based vaccines to global mass vaccination campaigns...
  5. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine
    Heng Kock Cheng
    KK Women's and Children Hospital, Singapore
    Southeast Asian J Trop Med Public Health 35:685-92
    ..5 degrees C, in the DTPa HBV- IPV-Hib group (50% of vaccinees)...
  6. Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine
    Michael E Pichichero
    University of Rochester Medical Center, Rochester, New York 14642, USA
    J Pediatr 151:43-9, 49.e1-2
    ..No group differences were observed in rates of symptoms for which parents sought medical advice. CONCLUSIONS: DTaP-HepB-IPV was highly immunogenic and well tolerated when coadministered with Hib and PCV-7 at 2, 4, and 6 months of age...
  7. Immunogenicity of a combined DTPa-HB vaccine co-administered with Haemophilus influenzae type B conjugate vaccine (PRP-T) for primary and booster vaccinations
    Humberto Bracco Neto
    Department of Pediatrics, Federal University of São Paulo, Rua Correa de Lemos 780, São Paulo, SP, Brazil
    Braz J Infect Dis 9:363-73
    ..No interference with antibody response was evident. The vaccines provided high immunogenicity, following both the primary vaccinations and the booster dose...
  8. Assessment of the compatibility of co-administered 7-valent pneumococcal conjugate, DTaP.IPV/PRP-T Hib and hepatitis B vaccines in infants 2-7 months of age
    David W Scheifele
    Vaccine Evaluation Center, BC Children s Hospital, 4500 Oak Street, Vancouver, BC, Canada V6H 3N1
    Vaccine 24:2057-64
    ..008) and HB responses were reduced (p=0.006) with concurrent dosing, the latter possibly from same thigh injection with DTaP.IPV/Hib. We conclude that PCV7, DTaP.IPV/Hib and HB are compatible with concurrent, separate injections...
  9. Safety and immunogenicity of a primary course and booster dose of a combined diphtheria, tetanus, acellular pertussis, hepatitis B and inactivated poliovirus vaccine
    Sirli Meriste
    Department of Infectious Diseases, Children s Clinic of Tartu University Hospital, Tartu, Estonia
    Scand J Infect Dis 38:350-6
    ..Both vaccine regimens were well tolerated and immunogenic, however the combined administration has the advantage of being administered as a single injection...
  10. Clinical experience with DTPw-HBV and DTPw-HBV/Hib combination vaccines
    Roman Prymula
    University of Defense, Department of Epidemiology, Faculty of Military Health Science, Hradec Kralove, Czech Republic
    Expert Opin Biol Ther 8:503-13
    ..Larger DTPw-based combination vaccines facilitate high coverage and protection against other childhood pathogens, such as hepatitis B (HBV) and ..
  11. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants
    C Olivier
    Hôpital L Mourier, Colombes, France
    Vaccine 26:3142-52
    ..In this study, PCV7 did not show any relevant influence on the immunogenicity and safety of the concurrently administered DTPa-IPV-HBV-Hib vaccine...
  12. A new DTPw-HBV/Hib vaccine is immunogenic and safe when administered according to the EPI (Expanded Programme for Immunization) schedule and following hepatitis B vaccination at birth
    Salvacion Gatchalian
    Research Institute for Tropical Medicine, Filinvest Corporate Centre, Alabang, Muntinlupa City, Manila, Philippines
    Hum Vaccin 1:198-203
    New combination vaccines and reliable sources of vaccine components are essential to ensure the success of mass immunisation programmes in the 21st century...
  13. Four is better than nine. a combined diphtheria-tetanus-pertussis-hepatitis B-Haemophilus influenzae type b vaccine for routine immunization in Malaysia
    Swee Lan Wong
    Pediatric Department, Hospital Tuanku Jaafar, Seremban, Negeri Sembilan, Malaysia
    Southeast Asian J Trop Med Public Health 39:474-83
    ..Use of the combined DTPw-HBV/Hib vaccine can reduce the required number of injections from nine to four in the first few months of life...
  14. The immunogenicity of oral poliomyelitis vaccine in a primary vaccination series at 2, 4 and 6 months given concurrently with Hib, hepatitis B and diphtheria, tetanus and whole-cell pertussis vaccines administered as three separate injections or as a comb
    Katharine Hogg
    Department of Microbiology and Immunology, Microbiological Diagnostic Unit, Public Health Laboratory, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Vic. 3010, Australia
    Vaccine 21:2906-10
    The increasing number of infant immunisations has spurred development of novel combination vaccines. This investigation assesses the immunogenicity of oral poliomyelitis vaccine (OPV) under current and possible new conditions, to help ..
  15. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjug
    Juan C Tejedor
    Móstoles Hospital, Madrid, Spain
    Pediatr Infect Dis J 25:713-20
    ..CONCLUSIONS: Coadministration of DTaP-HBV-IPV/Hib or DTaP-IPV/Hib with 2 doses of MenC-TT conjugate vaccine is safe, well tolerated, and immunogenic, with no impairment of the response to the coadministered antigens...
  16. [Vaccination against pneumococci and hepatitis B in the Dutch National Immunisation Programme]
    H J Boot
    Rijksinstituut voor Volksgezondheid en Milieu RIVM, Centrum Infectieziektebestrijding CIb, Postbus I, 3720 BA Bilthoven
    Ned Tijdschr Geneeskd 151:172-6
    ..This will also generate greater insight into the efficacy of the different vaccination schemes and intervention programmes to prevent vertical transmission of the virus...
  17. The use of combination vaccines has improved timeliness of vaccination in children
    Helen Kalies
    Department of Pediatric Epidemiology, Institute for Social Pediatrics and Adolescent Medicine of Ludwig Maximilians University, Munich, Germany
    Pediatr Infect Dis J 25:507-12
    ..We examined whether the use of combination vaccines has improved the timing of these vaccinations...
  18. Immunogenicity and safety of combined diphtheria tetanus whole cell pertussis hepatitis B/ Haemophilus influenzae type b vaccine in Indian infants
    S B Bavdekar
    Seth G S Medial College and K E M Hospital, Mumbai, India
    Indian Pediatr 44:505-10
    ..CONCLUSION: The combination DTPw-HBV/Hib vaccine is immunogenic (for the antigens tested), safe and well tolerated in Indian infants...
  19. Simultaneous vaccination of Chinese applicants for a United States immigrant visa
    Li Hua
    Guangdong International Travel Healthcare Center, Guangzhou 510130, China
    Travel Med Infect Dis 6:130-6
    ..Our data suggest that more Chinese people should be encouraged to receive simultaneous vaccination if the time is limited so as to reduce the risk of vaccine-preventable diseases...
  20. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants
    F Zepp
    Children s Hospital, Johannes Gutenberg University, Langenbeckstrasse 1, 55101 Mainz, Germany
    Vaccine 22:2226-33
    ....
  21. Immunogenicity and reactogenicity of combined versus separately administered DTPw-HBV and Hib vaccines given to healthy infants at 2, 4 and 6 months of age, with a booster at 18 months
    Stella Riedemann
    Universidad Austral de Chile, Valdivia, Chile
    Int J Infect Dis 6:215-22
    ..Furthermore, these results demonstrate the tolerability of a fourth (booster) administration, where the addition of the Hib vaccine to DTPw-HBV did not lead to an increase in the overall reactogenicity...
  22. The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-IPV-Hib vaccine
    H J Schmitt
    Pediatric Infectious Diseases, Johannes Gutenberg University, Langenbeckstr 1, D 55101 Mainz, Germany
    Vaccine 21:3653-62
    ....
  23. Safety and reactogenicity of a novel DTPa-HBV-IPV combined vaccine given along with commercial Hib vaccines in comparison with separate concomitant administration of DTPa, Hib, and OPV vaccines in infants
    Fred Zepp
    Children s Hospital, Pediatric Immunology and Infectious Diseases, Johannes Gutenberg University, Mainz, Germany
    Pediatrics 109:e58
    OBJECTIVE: Combination vaccines simplify vaccine administration and have the potential to promote compliance and cost-effectiveness by decreasing the number of injections needed to immunize a child...
  24. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines
    Henry Shinefield
    University of California School of Medicine, San Francisco, USA
    Pediatr Infect Dis J 25:287-92
    ..Limited data from an exploratory analysis indicate that MMRV can be administered concomitantly with DTaP. Concomitant administration of MMRV, Hib/HepB and DTaP is well-tolerated...
  25. Immunogenicity and safety of a combined hepatitis A and B vaccine administered concomitantly with either a measles-mumps-rubella or a diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis vaccine mixed with a Haemophilus influenzae type b conju
    V Usonis
    Centre of Paediatrics, Vilnius University, P O Box 2561, 2009 Vilnius, Lithuania
    Vaccine 23:2602-6
    ..All vaccines were well tolerated...
  26. DTPa-HBV-IPV vaccine for primary vaccination of infants
    Terry Nolan
    Vaccine and Immunisation Research Group, Murdoch Childrens Research Institute and School of Population Health, University of Melbourne, Melbourne, Victoria, Australia
    J Paediatr Child Health 43:587-92
    AIM: Combined vaccines have an increasingly important role to play in delivering these antigens acceptably...
  27. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content
    Khin Hla Hla
    Pediatric Unit No. 2, Military Hospital, Dagon Township, Yangon, Myanmar
    Pediatr Infect Dis J 25:706-12
    BACKGROUND: Combined vaccines containing diphtheria-tetanus-pertussis whole-cell (DTPw), Haemophilus influenzae type b (Hib), and hepatitis-B vaccines are essential for the continuing success of vaccination programs in developing nations...
  28. New combination vaccines still need a boost
    A J Pollard
    University of Oxford, Level 4, John Radcliffe Hospital, Oxford OX3 9DU, UK
    Arch Dis Child 92:1-2
  29. Combination vaccine use and vaccination quality in a managed care population
    Laura E Happe
    Xcenda, Palm Harbor, FL 34685, USA
    Am J Manag Care 13:506-12
    ..5% (324/865) of the reference cohort, P = .001. CONCLUSIONS: Receipt of DTaP/HepB/IPV was associated with improved coverage and age-appropriate immunization in a managed care population...
  30. Impact of the introduction of a combined Haemophilus B conjugate vaccine and hepatitis B recombinant vaccine on vaccine coverage rats in a large West Coast health maintenance organization
    Robert L Davis
    Center for Health Studies, Group Health Cooperative, Seattle, WA 98195, USA
    Pediatr Infect Dis J 22:657-8
    ..We evaluated the effect of introduction of a combined hepatitis B-Haemophilus influenzae b vaccine on vaccine coverage rates in a large health maintenance organization and found a modest improvement in up-to-date immunization status...
  31. Post-licensure comparative study of unusual high-pitched crying and prolonged crying following COMVAX and placebo versus PedvaxHIB and RECOMBIVAX HB in healthy infants
    Karen M Kaplan
    Merck and Co Inc, PO Box 4, BL 1 7, West Point, PA 19486, USA
    Vaccine 21:181-7
    ....
  32. Safety and immunogenicity of a pentavalent combination vaccine (diphtheria, tetanus, acellular pertussis, polio, and haemophilus influenzae type B conjugate) when administered as a fourth dose at 15 to 18 months of age
    D W Scheifele
    Vaccine Evaluation Center, British Columbia s Children s Hospital, Vancouver, British Columbia, Canada
    Hum Vaccin 1:180-6
    ..The fourth dose was well tolerated in all age groups. Toddlers at 15, 16, 17 or 18 months of age are equally suitable recipients for booster immunization with the DTaP-IPV//PRP-T vaccine...
  33. Primary vaccination with a new heptavalent DTPw-HBV/Hib-Neisseria meningitidis serogroups A and C combined vaccine is well tolerated
    Angkool Kerdpanich
    Infectious Disease Unit, Department of Pediatrics, Phramongkutklao Hospital, Bangkok, Thailand
    Int J Infect Dis 12:88-97
    ..CONCLUSION: Overall, the heptavalent and pentavalent vaccines had similar safety profiles. The difference observed in percentage of subjects with fever >39 degrees C did not lead to differences in medically attended visits for fever...
  34. Booster vaccination with hexavalent DTPa-HBV-IPV/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV/Hib + HBV administered separately
    R Saenger
    GlaxoSmithKline GmbH and Co KG, Theresienhoehe 11, 80339, Munich, Germany
    Vaccine 23:1135-43
    ..The hexavalent DTPa-HBV-IPV/Hib vaccine and the DTPa-IPV/Hib and HBV vaccines administered separately have similar good reactogenicity and safety profiles when given as booster doses in the second year of life...
  35. A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety
    Eric Mallet
    Charles Nicolle University Hospital, Rouen, France
    Vaccine 22:1343-57
    ..Hexavac provided immunity against six important childhood diseases with a single injection at each visit...
  36. Primary and booster vaccination with DTPw-HB/Hib pentavalent vaccine in Costa Rican children who had received a birth dose of hepatitis B vaccine
    Idis Faingezicht
    Hospital Nacional de Niños, San Jos, Costa Rica, Spain
    Rev Panam Salud Publica 12:247-57
    ..Thus, this study in Costa Rican infants supports the routine use of the pentavalent DTPw-HB/Hib vaccine as part of childhood vaccination programs in Latin America and the Caribbean...
  37. Safety and immunogenicity of pneumococcal conjugate vaccine in combination with diphtheria, tetanus toxoid, pertussis and Haemophilus influenzae type b conjugate vaccine
    Stephen K Obaro
    Imperial College School of Medicine, London, United Kingdom
    Pediatr Infect Dis J 21:940-7
    ..77, 7.68 in the control group; 5.15 IU/ml, 95% CI 4.39, 6.03 in the combined group; P= 0.02). However, all vaccinees achieved protective antibody values. CONCLUSION: The combination of TETRAMUNE and PnCV is safe and immunogenic...
  38. A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine
    Steven Black
    Kaiser Permanente Vaccine Study Center, 1 Kaiser Plaza, 16th Floor, Oakland, CA, USA
    Expert Rev Vaccines 4:793-805
    Ideally, combination vaccines should not only be safe and effective, but also integrate smoothly into the vaccination schedule and provide advantages over the use of separately administered vaccines. Pentaceltrade mark (Sanofi Pasteur Ltd...
  39. Dose response of CRM197 and tetanus toxoid-conjugated Haemophilus influenzae type b vaccines
    Robin E Huebner
    Respiratory and Meningeal Pathogens Research Unit of the Medical Research Council, National Health Laboratory Service and the University of the Witwatersrand, Johannesburg, South Africa
    Vaccine 23:802-6
    ..Our data suggest that doses of these vaccines of > or =1.25 microg may be sufficient to stimulate an immune response that offers both short and longer term protection from invasive Hib disease...
  40. Diphtheria-tetanus-pertussis (DTP) combination vaccines and evaluation of pertussis immune responses
    Fabrice Godfroid
    Research and Development, GlaxoSmithKline Biologicals, Rue de l'Institut 89, B-1330 Rixensart, Belgium
    Int J Med Microbiol 294:269-76
    Diphtheria-tetanus-pertussis (DTP) combination vaccines based on inactivated whole-cell Bordetella pertussis (DTPw) or purified acellular pertussis components (DTPa) facilitate vaccine administration and will allow further co-..
  41. A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants
    David Pace
    Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Department of Paediatrics, University of Oxford, Churchill Hospital, Headington, Oxford, OX3 7LJ, UK
    Pediatr Infect Dis J 26:1057-9
    ..SBA MenC titers > or =1:8 and anti-PRP concentrations > or =0.15 microg/mL were measured in 99.2% and 100%, respectively, of the infants receiving Hib-MenC-TT...
  42. Evaluation of the immunogenicity and reactogenicity of a DTPa-HBV-IPV Combination vaccine co-administered with a Hib conjugate vaccine either as a single injection of a hexavalent combination or as two separate injections at 3, 5 and 11 months of age
    Giovanni Gabutti
    Laboratory of Hygiene, Di S Te B A University of Lecce, Lecce, Italy
    Scand J Infect Dis 36:585-92
    ....
  43. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent
    Steven B Black
    Kaiser Permanente Vaccine Study Center, Oakland, CA, USA
    Pediatr Infect Dis J 25:306-11
    ..These results support concomitant administration of PCV7 with MMR, varicella and Hib as part of the recommended immunization schedule for children 12-15 months of age...
  44. Safety of DTaP-IPV-HIb-HBV hexavalent vaccine in very premature infants
    Giacomo Faldella
    Istituto di Pediatria Preventiva e Neonatologia, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti 11, 40138 Bologna, Italy
    Vaccine 25:1036-42
    ..Nevertheless, it is advisable to immunize and monitor them at 8 weeks before discharge instead of possibly delaying immunization for several weeks and not monitor them...
  45. Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study
    Scott A Halperin
    Department of Pediatrics, Dalhousie University and the IWK Health Centre, Halifax, NS
    Clin Invest Med 25:243-51
    ..CONCLUSIONS: The meningococcal C conjugate vaccine can be safely and effectively administered at the same visit as the other vaccine antigens routinely given to infants in Canada...
  46. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants
    M Knuf
    Pediatric Infectious Disease, Johannes Gutenberg University, Langenbeckstr. 1, D-55101 Mainz, Germany
    Vaccine 24:4727-36
    ..These results support the coadministration of PVC7 with DTPa-HBV-IPV/Hib as part of the routine immunization schedule for infants and children...
  47. Economic evaluation of a combined DTPa, hepatitis B, polio, Hib vaccine. Potential impact of the introduction of Infanrix-Hexa in the French childhood immunisation schedule
    Francis Fagnani
    CEMKA, 43 Boulevard Maréchal Joffre, 92340 Bourg la Reine, France
    Eur J Health Econ 5:143-9
    ..20 euro per child, or about 21 million euro for an annual cohort of 760,000 births (total cost, 35 million euro). The number of infants protected against hepatitis B could increase from 230,000 in the current situation to about 600,000...
  48. Use of a new combined vaccine in pediatric practices
    Gary L Freed
    Child Health Evaluation and Research Unit, University of Michigan, Ann Arbor, Michigan 48109 0456, USA
    Pediatrics 118:e251-7
    ..Also, the role of the availability of a given vaccine through the Vaccines for Children program is important in its adoption into practice...
  49. Long-term antibody persistence in children primed and boosted with a DTPw-HBV vaccine at 2, 4, 6, 18, months of age
    Yong Poovorawan
    Center of Excellence in Viral Hepatitis Research, Department of Paediatrics, Faculty of Medicine, Chulalongkorn University and Hospital, Bangkok, Thailand
    Vaccine 26:1535-40
    ..2 and 100% subjects were seroprotected against diphtheria and tetanus, respectively; > or =78.3% subjects were seropositive for pertussis. The results demonstrate long-term antibody persistence induced by combined DTPw-HBV vaccine...
  50. [Advantages of hexavalent vaccines]
    J Gaudelus
    Service de pédiatrie, CHU Jean Verdier, Avenue du 14 Juillet, 93140 Bondy, France
    Arch Pediatr 10:263s-266s
  51. Antibody persistence after primary vaccination with a hexavalent DTPa-HBV-IPV/HiB vaccine coadministered with a meningococcal C-CRM197 vaccine and response to a DTPa-IPV/HiB booster at 18 months of age
    Juan-Carlos Tejedor
    Hospital de Móstoles, Madrid, Spain
    Pediatr Infect Dis J 25:943-5
    ..6% (diphtheria, tetanus, polio and polyribosylribitol phosphate) after booster vaccination. The booster was well-tolerated (fever >39.5 degrees C after <2% of doses; large swelling reactions after 6.3% of doses)...
  52. Educating teens about vaccines
    Georgianna Hernandez
    J Pediatr Health Care 20:342-9
  53. Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate Vaccine
    Irmingard Tichmann-Schumann
    Medical Practice, Munich, Germany
    Pediatr Infect Dis J 24:70-7
    ..8% of the booster vaccine doses. CONCLUSION: Coadministration of the DTPa-HBV-IPV/Hib and 7vPn vaccines at separate injection sites during the same vaccination visit was effective and safe...
  54. The impact of DTaP-IPV-HB vaccine on use of health services for young infants
    Lindsay A Thompson
    Division of General Pediatrics, University of Florida, Gainesville, FL 32608, USA
    Pediatr Infect Dis J 25:826-31
    ..These findings reveal a conflict between the obligation of timely and efficient vaccination with the medical management of febrile young infants...
  55. Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection
    S Esposito
    Pediatric Department I, University of Milan, Milan, University of Palermo, Palermo, Italy
    Infect Immun 69:4516-20
    ..pertussis...
  56. Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants
    S H Yeh
    UCLA Center for Vaccine Research, Research and Education Institute, Torrance, CA, USA
    Pediatr Infect Dis J 20:973-80
    ..DTaP-HB-IPV and DTaP-HB combination vaccines had safety and immunogenicity equivalent to those of standard individually administered vaccines...